JW (Cayman) Therapeutics Co. Ltd. (JNY) Stock Statistics & Valuation Metrics

JW (Cayman) Therapeutics Co. Ltd. has a market cap or net worth of EUR 116.94M. The enterprise value is EUR 507.99M.

Market Cap

EUR 116.94M

Enterprise Value

EUR 507.99M

JW (Cayman) Therapeutics Co. Ltd. has 416,883,360 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

416,883,360

Owned by Insiders

―

Owned by Institutions

0.16%

JW (Cayman) Therapeutics Co. Ltd.’s return on equity (ROE) is -0.97 and return on invested capital (ROIC) is -29.51%.

Return on Equity (ROE)

-0.97

Return on Assets (ROA)

-0.55

Return on Invested Capital (ROIC)

-29.51%

Return on Capital Employed (ROCE)

-0.41

Revenue Per Employee

911.92K

Profits Per Employee

-1.79M

Employee Count

303

Asset Turnover

0.28

Inventory Turnover

2.54

The current PE Ratio of JW (Cayman) Therapeutics Co. Ltd. is -2.83. JW (Cayman) Therapeutics Co. Ltd.’s PEG ratio is -0.05.

PE Ratio

-2.83

PS Ratio

3.30

PB Ratio

2.08

Price to FCF

-8.42

Price to Operating Cash Flow

-8.60

PEG Ratio

-0.05

In the last 12 months, JW (Cayman) Therapeutics Co. Ltd. had revenue of 276.31M and earned -540.92M in profits. Earnings per share was -1.30.

Revenue

276.31M

Gross Profit

118.91M

Operating Income

-241.71M

Pretax Income

-537.93M

Net Income

-540.92M

EBITDA

-159.83M

Earnings Per Share (EPS)

-1.30

In the last 12 months, operating cash flow was -109.52M and capital expenditures -2.44M, giving a free cash flow of -111.96M billion.

Operating Cash Flow

-109.52M

Free Cash Flow

-111.96M

Free Cash Flow per Share

-0.27

JW (Cayman) Therapeutics Co. Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-11.89%

Earnings Yield

-35.44%

Beta

0.83

52-Week Price Change

-32.14%

50-Day Moving Average

0.26

200-Day Moving Average

0.22

Relative Strength Index (RSI)

51.27

Average Volume (3m)

―

JW (Cayman) Therapeutics Co. Ltd. upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).

Last Earnings Date

Aug 27, 2026

Next Earnings Date

Apr 01, 2027

Ex-Dividend Date

―

JW (Cayman) Therapeutics Co. Ltd. as a current ratio of 1.45, with Debt / Equity ratio of 47.20%

Current Ratio

1.45

Quick Ratio

1.29

Debt to Market Cap

0.25

Net Debt to EBITDA

1.51

Interest Coverage Ratio

-21.70

In the past 12 months, JW (Cayman) Therapeutics Co. Ltd. has paid 2.99M in taxes.

Income Tax

2.99M

Effective Tax Rate

-0.01

JW (Cayman) Therapeutics Co. Ltd. EV to EBITDA ratio is -4.03, with an EV/FCF ratio of -7.19.

EV to Sales

2.82

EV to EBITDA

-4.03

EV to Free Cash Flow

-7.19

EV to Operating Cash Flow

-7.35

JW (Cayman) Therapeutics Co. Ltd. has EUR 392.02M in cash and marketable securities with EUR 254.85M in debt, giving a net cash position of EUR 137.17M billion.

Cash & Marketable Securities

EUR 392.02M

Total Debt

EUR 254.85M

Net Cash

EUR 137.17M

Net Cash Per Share

EUR 0.33

Tangible Book Value Per Share

EUR 0.64

Gross margin is 39.80%, with operating margin of -95.03%, and net profit margin of -116.75%.

Gross Margin

39.80%

Operating Margin

-95.03%

Pretax Margin

-115.70%

Net Profit Margin

-116.75%

EBITDA Margin

-69.90%

EBIT Margin

-95.03%

The average price target for JW (Cayman) Therapeutics Co. Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target

―

Price Target Upside

―

Analyst Consensus

―

Analyst Count

―

Revenue Growth Forecast

55.89%

EPS Growth Forecast

47.77%

Smart Score

7

AI Score

―